Patent ID: 11925663
Assignee: ATARA BIOTHERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 20:
21. A method of treating a solid malignant tumor in a human patient comprising: (a) administering to the human patient a population of human cells comprising antigen-specific T cells that are specific for one or more antigens of the solid malignant tumor, said antigen-specific T cells having been generated by ex vivo sensitizing human T cells to the one or more antigens, wherein the antigen-specific T cells are not genetically engineered to be specific for the one or more antigens, wherein the population of human cells contains at least 70% T cells, and wherein the solid malignant tumor is a lymphoma; (b) monitoring the human patient for an indication of tumor flare, wherein the tumor flare is a clinical reaction to the administration of the population of human cells that is manifested as swelling of the tumor; (c) stopping treatment of the human patient with the population of human cells because the human patient has developed tumor flare that is life-threatening or deemed an excessive risk by the treating physician; and (d) re-initiating treatment of the human patient with the population of human cells when the tumor flare subsides or decreases after stopping treatment.